Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma
- 6 May 2015
- journal article
- Published by Springer Science and Business Media LLC in Tumor Biology
- Vol. 36 (10), 7797-7806
- https://doi.org/10.1007/s13277-015-3520-1
Abstract
Stathmin (STMN1) regulates microtubule dynamics by promoting depolymerization of microtubules and/or preventing polymerization of tubulin heterodimers. Several studies have shown that overexpression of STMN1 has been linked to chemoresistance of paclitaxel and vinblastine in tumor cells. This study aimed to investigate the effects of STMN1 silencing on chemosensitivities of paclitaxel or vinblastine in esophageal squamous cell carcinoma (ESCC). Immunocytochemistry and immunofluorescence assays showed that STMN1 gene was highly expressed in Eca109 and TE-1 cells. We demonstrated that lentiviral-mediated STMN1 short hairpin RNA (shRNA) specifically and efficiently downregulated STMN1 expression in Eca109 and TE-1 cells. The sensitivity of STMN1-silencing shRNA-transfected Eca109 and TE-1 cells increased 191.4- and 179.3-fold to paclitaxel, and 21.3- and 28.4-fold to vincristine, respectively. Flow cytometry and mitotic index assays showed that knockdown of STMN1 in Eca109 and TE-1 cells led to cell cycle arrest in G2/M phase. After treatment with paclitaxel or vincristine, STMN1-silencing shRNA-transfected Eca109 and TE-1 cells were more likely to enter G2 but less likely to enter mitosis than control cells. Therefore, these data suggests that silencing STMN1 gene could increase sensitivity of ESCC to paclitaxel and vincristine through G2/M phase block.Keywords
This publication has 19 references indexed in Scilit:
- Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivoJournal of Translational Medicine, 2013
- Effect of hOGG1 Over-Expression on Cisplatin Resistance in Esophageal Squamous Carcinoma CellsCancer Biotherapy & Radiopharmaceuticals, 2013
- DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal CancerInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Stathmin: a protein with many tasks. New biomarker and potential target in cancerEmerging Therapeutic Targets, 2011
- Reversal of Stathmin-Mediated Microtubule Destabilization Sensitizes Retinoblastoma Cells to A Low Dose of Antimicrotubule Agents: A Novel Synergistic Therapeutic InterventionInvestigative Ophthalmology & Visual Science, 2011
- Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma CellsMolecular Pharmacology, 2007
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cellsOncogene, 2003
- Catastrophic revelations about Op18/stathminTrends in Biochemical Sciences, 1996
- Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the EsophagusJNCI Journal of the National Cancer Institute, 1994